Meeting
2014 ASCO Annual Meeting
A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors.
Authors
Margaret K. Callahan
Memorial Sloan Kettering Cancer Center, New York, NY
Margaret K. Callahan , Patrick Alexander Ott , Kunle Odunsi , Stephane V. Bertolini , Linda S. Pan , Ralph Rudolph Venhaus , Joyson Joseph Karakunnel , F. Stephen Hodi , Jedd D. Wolchok
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Immunotherapy and Biologic Therapy
Clinical Trial Registration Number
NCT01975831
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3120^)
DOI
10.1200/jco.2014.32.15_suppl.tps3120
Abstract #
TPS3120^
Poster Bd #
182B
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
SELECT-4: Phase I dose escalation trial of selumetinib (AZD6244, ARRY-142886) in combination with durvalumab (MEDI4736) in patients with advanced solid tumors.
First Author: Pasi A. Janne
Poster
2015 ASCO Annual Meeting
A phase I study to evaluate the safety and tolerability of MEDI4736, an anti- programmed cell death-ligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors.
First Author: Patrick Alexander Ott
Poster
2017 ASCO Annual Meeting
Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) + tremelimumab (TRE) in patients with advanced solid tumors.
First Author: Margaret K. Callahan
Poster
2020 ASCO Virtual Scientific Program
Immune activation in first-in-human anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) phase I/II MATINS trial: Part I dose-escalation, safety, and efficacy results.
First Author: Petri Bono